Derajat Depresi Pasien Hepatitis C Kronis yang Mendapat Terapi PegIFN-α
DOI:
https://doi.org/10.21776/ub.jkb.2017.029.03.9Keywords:
Derajat depresi, hepatitis C kronis, pegIFNαAbstract
Disamping efek dari infeksi hepatitis C, pengobatan hepatitis C dengan menggunakan pegylated interferon alfa dikatakan memiliki efek samping berupa depresi. Untuk mengevaluasi gejala depresi pada pasien hepatitis C yang mendapatkan terapi pegylated interferon alfa di divisi Gastroentero-hepatologi RSUD Dr. Saiful Anwar Malang. Penilaian depresi dilakukan 1 kali, dengan menggunakan kuisioner Patient Health Questionnaire 9 (PHQ-9). Penelitian ini dilakukan antara tahun 2014-2015. Seluruh pasien hepatitis C yang mendapatkan terapi dengan pegylated interferon alfa, diberikan formulir kuisioner dari Patient Health Questionnaire (PHQ-9) untuk dievaluasi kondisi depresi yang terjadi. Dari keseluruhan pasien berjumlah 24 pasien, didapatkan hasil berupa depresi minimal sebanyak 9 pasien (37,5%), depresi ringan sebanyak 12 pasien (50%), depresi sedang sebanyak 2 pasien (8,3%) dan depresi sedang-berat sebanyak 1 pasien (4,2%). Rerata usia pasien adalah 53,55±12,13 (dalam tahun), dengan rentang usia 30-73 tahun. Jumlah pasien pria sama dengan jumlah pasien wanita (masing-masing 12 orang). Rerata lama terapi adalah 17,78±11,88 (dalam minggu). Genotipe terbanyak adalah genotipe 1 (16 pasien, 66,67%). Manifestasi depresi yang terbanyak adalah kelelahan yang terus menerus dan penurunan nafsu makan. Penelitian membuktikan adanya gangguan depresi pada pasien-pasien hepatitis C yang mendapat terapi pegylated interferon alfa (pegIFNα). Penilaian kondisi mental sebelum memulai terapi dan setelah selesai terapi, perlu dilakukan secara rutin untuk menilai adanya efek samping yang perlu ditangani secara lebih lanjut.
Kata Kunci: Derajat depresi, hepatitis C kronis, pegIFNα
Downloads
References
Malhotra S, Kaur N, Kumar P, Bhatia M and Hans C. Hepatitis C and Depression. Delhi Psychiatry Journal. 2011; 14(1): 143-148.
Schaefer M, Capuron L, Friebe A, et al. Hepatitis C Infection, Antiviral Treatment and Mental Health: A European Expert Consensus Statement. Journal of Hepatology. 2012; 57(6): 1379-1390.
Dieperink E, Willenbring M, and Ho SB. Neuropsychiatric Symptoms Associated with Hepatitis C and Interferon Alpha: A Review. The American Journal of Psychiatry. 2000; 157(6): 867-876.
Badrakalimuthu VR, Rumball D, and Chawla A. Hepatitis C: A Patient's Journey from a Psychiatrist's Perspective. Advances in Psychiatric Treatment. 2011; 17(5): 340-349.
Modabbernia A, Poutstchi H, and Malekzadeh R. Neuropsychiatric and Psychosocial Issues of Patients with Hepatitis C Infection: A Selective Literature Review. Hepatitis Monthly. 2013; 13(1): e8340.
Manns MP, Wedemeyer H, and Cornberg M. Treating Viral Hepatitis C: Efficacy, Side Effects, and Complications. Gut. 2006; 55(9): 1350-1359.
Kroenke K, Spitzer R, and Williams W. The PHQ-9: Validity of a Brief Depression Severity Measure. Journal of General Internal Medicine. 2001; 16(9): 606-613.
Foster GR. Quality of Life Considerations for Patients with Chronic Hepatitis C. Journal of Viral Hepatitis. 2009; 16(9): 605-611.
Pavlovic Z, Delic D, Maric NP, Vukovic O, and Jasovic-Gasic M. Depressive Symptoms in Patients with Hepatitis C Treated with Pegylated Interferon Alpha Therapy: A 24-week Prospective Study. Psychiatria Danubina. 2011; 23(4): 370-377.
Aspinall RJ and Pockros PJ. Review Article: The Management of Side-Effects during Therapy for Hepatitis C. Alimentary Pharmacology and Therapeutics. 2004; 20(9): 917-929.
Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and Mental Side Effects During Hepatitis C Treatment with Interferon Alfa and Ribavirin in Psychiatric Risk Groups. Hepatology. 2003; 37(2): 443-451.
Torres GV, Apicella E, D'Alterio E, Cecere AC, and Bellomo A. Chronic C Hepatitis, Interferon and Psychiatric Disorder. (Online) 2013. http://cdn.intechopen.com/pdfs/44873/InTech-Chronic_c_hepatitis_interferon_ and_ psychiatric_disorders.pdf. {diakses tanggal 14 April 2016].
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).